BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28026820)

  • 1. Mechanisms of angiogenesis in neoplasia.
    Sobocińska AA; Czarnecka AM; Szczylik C
    Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1166-1181. PubMed ID: 28026820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 3. Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin.
    Kotecki N; Penel N
    Curr Opin Oncol; 2016 Sep; 28(5):437-40. PubMed ID: 27428364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic drugs and tyrosine kinases.
    Tímár J; Döme B
    Anticancer Agents Med Chem; 2008 Jun; 8(5):462-9. PubMed ID: 18537529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 7. Is VEGF a predictive biomarker to anti-angiogenic therapy?
    Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
    Gotink KJ; Verheul HM
    Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC; Pulido EG; Guillén-Ponce C
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synopsis of angiogenesis inhibitors in oncology.
    Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis.
    Li X; Zhou J; Wang X; Li C; Ma Z; Wan Q; Peng F
    Biomed Pharmacother; 2023 Jul; 163():114806. PubMed ID: 37163782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
    Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
    Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic inhibition of angiogenesis.
    Zhang HT; Bicknell R
    Mol Biotechnol; 2003 Oct; 25(2):185-200. PubMed ID: 14526126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
    Scott AJ; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.